PL2803366T3 - Kompozycje do leczenia lub profilaktyki choroby związanej ze szczawianem - Google Patents

Kompozycje do leczenia lub profilaktyki choroby związanej ze szczawianem

Info

Publication number
PL2803366T3
PL2803366T3 PL14180734T PL14180734T PL2803366T3 PL 2803366 T3 PL2803366 T3 PL 2803366T3 PL 14180734 T PL14180734 T PL 14180734T PL 14180734 T PL14180734 T PL 14180734T PL 2803366 T3 PL2803366 T3 PL 2803366T3
Authority
PL
Poland
Prior art keywords
compositions
treating
related disease
preventing oxalate
oxalate
Prior art date
Application number
PL14180734T
Other languages
English (en)
Inventor
Harmeet Sidhu
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35510266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2803366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of PL2803366T3 publication Critical patent/PL2803366T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL14180734T 2004-06-15 2005-06-15 Kompozycje do leczenia lub profilaktyki choroby związanej ze szczawianem PL2803366T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/868,242 US8486389B2 (en) 1997-05-23 2004-06-15 Compositions and methods for treating or preventing oxalate-related disease
EP05786347.4A EP1771201B1 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease
EP14180734.7A EP2803366B1 (en) 2004-06-15 2005-06-15 Compositions for treating or preventing oxalate-related disease
PCT/US2005/021134 WO2005123116A2 (en) 2004-06-15 2005-06-15 Compositions and methods for treating or preventing oxalate-related disease

Publications (1)

Publication Number Publication Date
PL2803366T3 true PL2803366T3 (pl) 2018-12-31

Family

ID=35510266

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05786347T PL1771201T3 (pl) 2004-06-15 2005-06-15 Kompozycje i sposoby leczenia lub profilaktyki choroby związanej ze szczawianem
PL14180734T PL2803366T3 (pl) 2004-06-15 2005-06-15 Kompozycje do leczenia lub profilaktyki choroby związanej ze szczawianem

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05786347T PL1771201T3 (pl) 2004-06-15 2005-06-15 Kompozycje i sposoby leczenia lub profilaktyki choroby związanej ze szczawianem

Country Status (13)

Country Link
US (3) US8486389B2 (pl)
EP (2) EP2803366B1 (pl)
CN (2) CN104998253A (pl)
CY (2) CY1115745T1 (pl)
DK (2) DK1771201T3 (pl)
ES (2) ES2692148T3 (pl)
HK (1) HK1216080A1 (pl)
LT (1) LT2803366T (pl)
PL (2) PL1771201T3 (pl)
PT (2) PT2803366T (pl)
SI (2) SI1771201T1 (pl)
TR (1) TR201815200T4 (pl)
WO (1) WO2005123116A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
WO2003042380A2 (en) * 2001-10-05 2003-05-22 Ixion Biotechnology, Inc. Materials and methods for reducing oxalate concentrations in fluids
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20080317810A1 (en) * 2004-05-07 2008-12-25 Harmeet Sidhu Methods and Compositions for Reducing Oxalate Concentrations
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
US20080311101A1 (en) 2005-06-10 2008-12-18 Shenoy Bhami C Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals
ES2426258T3 (es) * 2005-12-14 2013-10-22 Oxthera Intellectual Property Ab Composiciones farmacéuticas que comprenden bacterias que reducen oxalato
ES2362897T3 (es) * 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
ES2412254T3 (es) 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Oxalato-descarboxilasa cristalizada y métodos de uso
ES2551719T3 (es) 2007-02-01 2015-11-23 Iams Europe B.V. Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
PL2449098T3 (pl) * 2009-07-02 2017-06-30 Oxthera Intellectual Property Ab Oczyszczanie i izolacja rekombinowanych enzymów rozkładających szczawian i cząstki suszone rozpryskowo zawierające enzymy rozkładające szczawian
ES2673269T3 (es) 2009-07-02 2018-06-21 Oxthera Intellectual Property Ab Purificación y aislamiento de enzimas de degradación de oxalato recombinantes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102725403A (zh) * 2009-11-25 2012-10-10 凯普托杰姆有限责任公司 草酸相关疾病治疗方法和组合物
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
EP3003358B1 (en) 2013-06-07 2021-03-24 Allena Pharmaceuticals Inc. Compositions and devices for dialysis
WO2015002588A1 (en) * 2013-07-05 2015-01-08 Oxthera Intellectual Property Ab Secretagogues derived from oxalobacter formigenes
CN107960105B (zh) 2015-04-02 2025-05-16 武汉康复得生物科技股份有限公司 用于降解不溶性和可溶性草酸的高效草酸降解酶
MA45226A (fr) 2016-06-13 2019-04-17 Oxthera Intellectual Property Ab Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
CA3048669A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2020018799A1 (en) 2018-07-18 2020-01-23 The University Of Chicago Compositions comprising sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
CN113454229A (zh) 2018-12-10 2021-09-28 诺沃梅生物技术股份有限公司 用于治疗高草酸尿症的方法和组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) * 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4888182A (en) 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5279827A (en) 1991-01-16 1994-01-18 Allegheny-Singer Research Institute Extract and pharmaceutical composition for treatment of calcium oxalate stone disease and viral infections
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
WO1994012622A1 (en) * 1992-11-30 1994-06-09 Zeneca Limited Oxalate decarboxylase
AU6701694A (en) * 1993-04-16 1994-11-08 Mccormick & Company, Inc. Encapsulation compositions
US5554147A (en) * 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
EP0764204B1 (en) 1994-05-18 2001-08-22 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US5604111A (en) * 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US6090628A (en) * 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US6214980B1 (en) * 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US6033719A (en) * 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
US20040120941A1 (en) 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
ATE444073T1 (de) 1997-05-23 2009-10-15 Oxthera Inc Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten
US6080404A (en) * 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
AU777977B2 (en) 1998-10-09 2004-11-04 General Mills Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
IT1309427B1 (it) * 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
JP2003501378A (ja) 1999-06-07 2003-01-14 ナノスフィアー、インコーポレーテッド 粒子の被覆方法およびその方法により製造した粒子
DE10026541A1 (de) 2000-05-27 2001-11-29 Zeiss Carl Vorrichtung zur präzisen Positionierung eines Bauteils, insbesondere eines optischen Bauteiles
WO2003042380A2 (en) 2001-10-05 2003-05-22 Ixion Biotechnology, Inc. Materials and methods for reducing oxalate concentrations in fluids
US7407668B2 (en) * 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
AU2003274918A1 (en) 2002-08-20 2004-03-11 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
US20080317810A1 (en) * 2004-05-07 2008-12-25 Harmeet Sidhu Methods and Compositions for Reducing Oxalate Concentrations
ES2426258T3 (es) * 2005-12-14 2013-10-22 Oxthera Intellectual Property Ab Composiciones farmacéuticas que comprenden bacterias que reducen oxalato
ES2362897T3 (es) 2005-12-16 2011-07-14 Oxthera, Inc. Composiciones y métodos para reducción del oxalato.
ES2412254T3 (es) 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Oxalato-descarboxilasa cristalizada y métodos de uso
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
US20040234514A1 (en) 2004-11-25
DK2803366T3 (en) 2018-11-05
HK1198922A1 (en) 2015-06-19
EP1771201A4 (en) 2011-01-19
EP2803366A3 (en) 2015-02-18
PT1771201E (pt) 2014-11-06
PT2803366T (pt) 2018-11-06
TR201815200T4 (tr) 2018-11-21
WO2005123116A2 (en) 2005-12-29
US10149866B2 (en) 2018-12-11
EP2803366A2 (en) 2014-11-19
LT2803366T (lt) 2018-12-27
CN101166421A (zh) 2008-04-23
CY1120782T1 (el) 2019-12-11
SI1771201T1 (sl) 2014-12-31
US20140030324A1 (en) 2014-01-30
US20190091268A1 (en) 2019-03-28
EP1771201A2 (en) 2007-04-11
US10653726B2 (en) 2020-05-19
EP2803366B1 (en) 2018-08-01
PL1771201T3 (pl) 2015-01-30
CY1115745T1 (el) 2017-01-25
EP1771201B1 (en) 2014-08-13
WO2005123116A3 (en) 2008-01-03
CN104998253A (zh) 2015-10-28
ES2692148T3 (es) 2018-11-30
HK1216080A1 (zh) 2016-10-14
SI2803366T1 (sl) 2018-12-31
ES2522898T3 (es) 2014-11-19
DK1771201T3 (da) 2014-11-03
US8486389B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
LT2803366T (lt) Kompozicijos, skirtos su oksalatu susijusių ligų gydymui arba prevencijai
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
PL1984357T3 (pl) Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
IL190991A0 (en) Agents for treating cardiopathy
AU2006279280A8 (en) Methods and compositions for treating neurological disease
IL185761A0 (en) Pharmaceutical compositions for treating diabetes
EP2076116A4 (en) COMPOSITIONS, METHODS, AND DEVICES FOR TREATING HEPATIC DISEASES
ZA200703908B (en) Compositions for HCV treatment
GB0421145D0 (en) Laundry treatment compositions
GB0420203D0 (en) Laundry treatment compositions
GB0817929D0 (en) Compositions for topical treatment
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
GB0411995D0 (en) Laundry treatment compositions
IL196638A0 (en) Methods and compositions for treating disease
GB0400802D0 (en) Compounds for the treatment of disease
PT1965816T (pt) Composições farmacêuticas e métodos de tratamento ou prevenção de uma doença associada a oxalato
AP2005003270A0 (en) Composition for the treatment of humans.
IL160892A0 (en) Disinfecting compositions
GB0522732D0 (en) Composition and method for treating disease
GB0507963D0 (en) Composition and method for treating disease
ZA200501156B (en) Lice treatment composition
EP1722782A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING OR TREATING HIV-1
GB0415352D0 (en) Compounds for the treatment of disease
GB0416712D0 (en) Laundry treatment compositions
GB0421147D0 (en) Laundry treatment compositions